尽管巨大的精力投入于癌症的生物医学研究，但癌症仍然是全球主要的健康问题。除了主流的治疗干预措施（即手术、化疗、免疫疗法和放疗）之外，抗癌疗法的进一步重要进展可能依赖于新的治疗范式的开发。为此，出现了一种新兴的方法，即利用非热低强度聚焦超声（LIFU）来处理癌症分子和/或针对癌症的化合物，从而以最小的副作用引起癌细胞死亡。细胞氧化还原平衡在肿瘤块的组成、大小和解剖位置上体现为能量代谢过程中的活性氧（ROS）的生成以及抗氧化能力。与健康细胞相比，癌症中“氧自由基”的含量较高，使其更容易破坏氧化还原平衡，因此，最好的选择之一是过度增加氧化应激以有选择地根除癌细胞。对LIFU对细胞氧化还原平衡的调节还知之甚少，因此，了解LIFU对癌细胞能量代谢的影响将具有极大的兴趣和实用性。本综述旨在提高我们对LIFU对癌细胞的影响的认识，特别是与超声治疗相关的氧化还原代谢。从而，为探索新的方法和设计联合抗癌疗法，特别是用于更快、更安全地根治耐药和转移性实体肿瘤铺平道路。版权所有 © 2023。Elsevier Inc. 发表。

Cancer is still a major health problem worldwide despite huge efforts being spent on its biomedical research. Beyond the mainstream therapeutic interventions (i.e., surgery, chemotherapy, immunotherapy and radiotherapy), further significant progresses in anticancer therapy could rely on the development of novel treatment paradigms. To this end, one emerging approach consists in the use of non-thermal low-intensity focused ultrasound (LIFU) for conditioning cancer molecules and/or cancer-targeted compounds, thereby leading to cancer cell death with least side-effects. Cellular redox homeostasis manifested as the generation of reactive oxygen species (ROS) during energy metabolism as well as the antioxidant capacity is interwoven to the composition, size and anatomical location of the tumor masses. The higher content of "oxide free radicals" in cancers makes them vulnerable to disruption of redox homeostasis than in the healthy cells and therefore, one of the best options for preferentially eradicating them is increasing their oxidative stress, excessively. A little is known about the modulation of cellular redox homeostasis by LIFU, and so it will be of great interest and utility to understand the effects of LIFU on the energy metabolism of cancer cells. This review is intended to improve our knowledge on the effect of LIFU on cancer cells with particular reference to its redox metabolism for ultrasound-based therapies. Thereby, it could pave the way for exploring novel methodologies and designing combined anti-cancer therapies, especially, for faster and safer eradication of drug resistant and metastasizing solid tumors.Copyright © 2023. Published by Elsevier Inc.